• Apeptico GmbH, of Vienna, Austria, said AP301, an orally inhaled peptide for edematous respiratory failure, was well tolerated in a Phase I trial. A Phase IIa trial with an aerosol formulation is slated to begin next year.
• DelMar Pharmaceuticals Ltd., of Vancouver, British Columbia, initiated an open-label Phase I/II trial of VAL-083 for refractory glioblastoma multiforme. VAL-083 is a bi- functional alkylating agent approved in China for chronic myelogenous leukemia and solid tumors.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter